Says regulatory submissions for CASGEVY in patients aged 5-11 years with SCD and TDT are expected in the first half of 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $90 from $93 at BofA
- Cathie Wood’s ARK Funds Had ‘One Heck of a Year’ — What’s Next for 2026?
- Cathie Wood’s ARK Adds to CRISPR Stock — Here’s What Else It Traded This Week
- Cathie Wood Adds to WeRide (WRD) and CRISPR, Trims Ibotta (IBTA) in Holiday Trades
- Cathie Wood’s Christmas Trades: ARK Invest Bets on WeRide and CRISPR